SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

USFDA completes cGMP inspection at OneSource Specialty Pharma’s SPD facility

02 Jul 2026 Evaluate

The United States Food and Drug Administration (USFDA) has conducted a routine current Good Manufacturing Practices (cGMP) inspection at OneSource Specialty Pharma’s Sterile Product Division (SPD) facility located at Opp. IIM, Bilekahalli, Bannerghatta Road, Bengaluru, from June 22, 2026 to June 30, 2026. The inspection has concluded with one observation. The company will respond to the observation comprehensively to FDA within the stipulated time frame.

OneSource Specialty Pharma is a multimodal specialty pharma CDMO with end-to-end capabilities across technology platforms and therapeutic modalities.

Onesource Specialty Share Price

1666.00 -21.40 (-1.27%)
03-Jul-2026 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1904.65
Dr. Reddys Labs. 1374.55
Cipla 1458.45
Zydus Lifesciences 1141.00
Lupin 2476.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: